The molecular biology and novel treatments of vestibular schwannomas: A review

Journal of Neurosurgery

Volumn 115, Issue 5, 2011, Pages 906-914

  Fong, Brendan ^a   Barkhoudarian, Garni ^a   Pezeshkian, Patrick ^a   Parsa, Andrew T ^b   Gopen, Quinton ^a   Yang, Isaac ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acoustic neuroma; Avastin; Merlin; Molecular biology; Neurofibromatosis type 2; Oncology; Treatment; VEGF; Vestibular schwannoma

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BEVACIZUMAB; ERLOTINIB; IPA 3; LAPATINIB; MERLIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; PTC 299; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ACOUSTIC NEURINOMA; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; EPISTAXIS; FATIGUE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MOLECULAR BIOLOGY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ENZYME INHIBITORS; HUMANS; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; SIGNAL TRANSDUCTION;

EID: 80655149532     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2011.6.JNS11131     Document Type: Review

References (126)

1. Abe T, Izumiyama H, Imaizumi Y, Kobayashi S, Shimazu M, Sasaki K, et al.: Staged resection of large hypervascular vestibular schwannomas in young adults. Skull Base 11:199-206, 2001 (Pubitemid 32904348)
2. Agrawal Y, Clark JH, Limb CJ, Niparko JK, Francis HW: Predictors of vestibular schwannoma growth and clinical implications. Otol Neurotol 31:807-812, 2010
3. Ahmad Z, Brown CM, Patel AK, Ryan AF, Ongkeko R, Doherty JK: Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. Otol Neurotol 31:460-466, 2010
4. Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, et al.: ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol 12:834-843, 2010
5. An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, et al.: Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated metaanalysis. Eur J Clin Pharmacol 66:813-821, 2010
6. Baek SY, Kim SU: Proliferation of human Schwann cells induced by neu differentiation factor isoforms. Dev Neurosci 20:512-517, 1998
7. Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q: Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 26:836-850, 2007
8. Bari ME, Forster DM, Kemeny AA, Walton L, Hardy D, Anderson JR: Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature. Br J Neurosurg 16:284-289, 2002
9. Battaglia A, Mastrodimos B, Cueva R: Comparison of growth patterns of acoustic neuromas with and without radiosurgery. Otol Neurotol 27:705-712, 2006 (Pubitemid 44180485)
10. Bernards A, Gusella JF: The importance of genetic mosaicism in human disease. N Engl J Med 331:1447-1449, 1994
11. Bianchi AB, Hara T, Ramesh V, Gao J, Klein-Szanto AJ, Morin F, et al.: Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 6:185-192, 1994 (Pubitemid 24188601)
12. Bosco EE, Nakai Y, Hennigan RF, Ratner N, Zheng Y: NF2- deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene 29:2540-2549, 2010
13. Bourn D, Carter SA, Mason S, Gareth D, Evans R, Strachan T: Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet 3:813-816, 1994 (Pubitemid 24148628)
14. Bretcher A, Edwards K, Fehon R: ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3:586-599, 2002
15. Carroll SL, Miller ML, Frohnert PW, Kim SS, Corbett JA: Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci 17:1642-1659, 1997 (Pubitemid 27089810)
16. Cayé-Thomasen P, Borup R, Stangerup SE, Thomsen J, Nielsen FC: Deregulated genes in sporadic vestibular schwannomas. Otol Neurotol 31:256-266, 2010
17. Cayé-Thomasen P, Werther K, Nalla A, Bøg-Hansen TC, Nielsen HJ, Stangerup SE, et al.: VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26:98-101, 2005 (Pubitemid 40130217)
18. CBTRUS: Central Brain Tumor Registry of the United States 1997 Annual Report. Chicago: Central Brain Tumor Registry of the United States, 1998
19. CBTRUS: Primary Brain Tumors in the United States: Statistical Report, 1995-1999. Chicago: Central Brain Tumor Registry of the United States, 2002-2003
20. Clark JJ, Provenzano M, Diggelmann HR, Xu N, Hansen SS, Hansen MR: The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study. Otol Neurotol 29:846-853, 2008
21. Cole BK, Curto M, Chan AW, McClatchey AI: Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol 28:1274-1284, 2008 (Pubitemid 351214130)
22. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI: Contact-dependent inhibition of EGFR signaling by Nf2/ Merlin. J Cell Biol 177:893-903, 2007 (Pubitemid 46873094)
23. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, et al.: An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 15:322-331, 2008 (Pubitemid 351508427)
24. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME: Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 43:289-294, 2006
25. Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, et al.: A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalance, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841-846, 1992 (Pubitemid 23035205)
26. Fernandez-Valle C, Gwynn L, Wood PM, Carbonetto S, Bunge MB: Anti-beta 1 integrin antibody inhibits Schwann cell myelination. J Neurobiol 25:1207-1226, 1994
27. Fernandez-Valle C, Tang Y, Ricard J, Rodenas-Ruano A, Taylor A, Hackler E, et al.: Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 31:354-362, 2002 (Pubitemid 35154443)
28. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003 (Pubitemid 36749215)
29. Flaiz C, Ammoun S, Biebl A, Hanemann CO: Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Brain Pathol 19:27-38, 2009
30. Flaiz C, Chernoff J, Ammoun S, Peterson JR, Hanemann CO: PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp Neurol 218:137-144, 2009
31. Flaiz C, Utermark T, Parkinson DB, Poetsch A, Hanemann CO: Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells. Glia 56:506-515, 2008
32. Fucci MJ, Buchman CA, Brackmann DE, Berliner KI: Acoustic tumor growth: implications for treatment choices. Am J Otol 20:495-499, 1999 (Pubitemid 30117043)
33. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa- Kawakita M, Abramowski V, Goutebroze L, et al.: Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 14:1617-1630, 2000 (Pubitemid 30460911)
34. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, et al.: Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100:1092-1103, 2008
35. Hadfield KD, Smith MJ, Urquhart JE, Wallace AJ, Bowers NL, King AT, et al.: Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29:6216-6221, 2010
36. Halliday AL, Sobel RA, Martuza RL: Benign spinal nerve sheath tumors: their occurrence sporadically and in neurofibromatosis types 1 and 2. J Neurosurg 74:248-253, 1991
37. Hansen MR, Clark JJ, Gantz BJ, Goswami PC: Effects of ErbB2 signaling on the response of vestibular schwannoma cells to gamma-irradiation. Laryngoscope 118:1023-1030, 2008 (Pubitemid 351787273)
38. Hansen MR, Roehm PC, Chatterjee P, Green SH: Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia 53:593-600, 2006
39. Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 (2 Suppl):21-26, 2004
40. Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH: The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol 29:1472-1486, 2009
41. Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, Florens L, et al.: Lentiviral Vpr usurps Cul4- DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proc Natl Acad Sci U S A 104:11778-11783, 2007 (Pubitemid 47175089)
42. Hughes SC, Fehon RG: Understanding ERM proteins - the awesome power of genetics finally brought to bear. Curr Opin Cell Biol 19:51-56, 2007 (Pubitemid 46123970)
43. Hung G, Colton J, Fisher L, Oppenheimer M, Faudoa R, Slattery W, et al.: Immunohistochemistry study of human vestibular nerve schwannoma differentiation. Glia 38:363-370, 2002
44. Jääskeläinen J, Paetau A, Pyykkö I, Blomstedt G, Palva T, Troupp H: Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg 80:541-547, 1994 (Pubitemid 24073018)
45. James MF, Manchanda N, Gonzalez-Agosti C, Hartwig JH, Ramesh V: The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem J 356:377-386, 2001 (Pubitemid 32532348)
46. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, et al.: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11:6414-6421, 2005 (Pubitemid 41338977)
47. Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO: Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet 12:1211-1221, 2003 (Pubitemid 36722601)
48. Kissil JL, Blakeley JO, Ferner RE, Huson SM, Kalamarides M, Mautner VF, et al.: What's new in neurofibromatosis? Proceedsings from the 2009 NF conference: new frontiers. Am J Med Genet Part A 152A:269-283, 2009
49. Kissil JL, Johnson KC, Eckman MS, Jacks T: Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 277:10394-10399, 2002 (Pubitemid 34968159)
50. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T: Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 12: 841-849, 2003 (Pubitemid 37352778)
51. Kluwe L, Mautner VF: Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet 7:2051-2055, 1998 (Pubitemid 28546413)
52. LaJeunesse DR, McCartney BM, Fehon RG: Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol 141:1589-1599, 1998 (Pubitemid 28309173)
53. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI: NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 17:1090-1100, 2003 (Pubitemid 36534984)
54. Lanman TH, Brackmann DE, Hitselberger WE, Subin B: Report of 190 consecutive cases of large acoustic tumors (vestibular schwannoma) removed via the translabyrinthine approach. J Neurosurg 90:617-623, 1999 (Pubitemid 29152848)
55. Laulajainen M, Muranen T, Carpén O, Grönholm M: Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton. Oncogene 27:3233-3243, 2008 (Pubitemid 351733388)
56. Lee DJ, Westra WH, Staecker H, Long D, Niparko JK, Slattery WH III: Clinical and histopathologic features of recurrent vestibular schwannoma (acoustic neuroma) after stereotactic radiosurgery. Otol Neurotol 24:650-660, 2003 (Pubitemid 36886283)
57. Li Q, Nance MR, Kulikauskas R, Nyberg K, Fehon R, Karplus P, et al.: Self-masking in an intact ERM-merlin protein: an active role for the central apical-helical domain. J Mol Biol 365: 1446-1459, 2007 (Pubitemid 46055267)
58. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, et al.: Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140: 477-490, 2010
59. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al.: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993-1999, 2008
60. Linskey ME: Stereotactic radiosurgery versus stereotactic radiotherapy for patients with vestibular schwannoma: a Leksell Gamma Knife Society 2000 debate. J Neurosurg 93 (Suppl 3):90-95, 2000
61. Linthicum FH Jr, Brackmann DE: Bilateral acoustic tumors. A diagnostic and surgical challenge. Arch Otolaryngol 106: 729-733, 1980 (Pubitemid 11194181)
62. Louis DN, Ramesh V, Gusella JF: Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol 5:163-172, 1995
63. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J: Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779-786, 2008
64. MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio MP, Pulaski K, et al.: Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 55:314-320, 1994 (Pubitemid 24233215)
65. Maitra S, Kulikauskas RM, Gavilan H, Fehon RG: The tumor suppressors Merlin and Expanded function cooperatively to modulate receptor endocytosis and signaling. Curr Biol 16:702-709, 2006
66. Marchionni MA, Goodearl AD, Chen MS, Bermingham- McDonogh O, Kirk C, Hendricks M, et al.: Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362:312-318, 1993 (Pubitemid 23101302)
67. Maurel P, Salzer JL: Axonal regulation of Schwann cell proliferation and survival and the initial events of myelination requires PI 3-kinase activity. J Neurosci 20:4635-4645, 2000 (Pubitemid 30396629)
68. Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, et al.: The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 38:880-886, 1996 (Pubitemid 26125548)
69. Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, et al.: Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14-18, 2010
70. McCall CM, Miliani de Marval PL, Chastain PD II, Jackson SC, He YJ, Kotake Y, et al.: Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development. Mol Cell Biol 28:5621-5633, 2008
71. McClatchey A, Fehon R: Merlin and the ERM proteins- regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol 19:198-206, 2009
72. McLaughlin ME, Kruger GM, Slocum KL, Crowley D, Michaud NA, Huang J, et al.: The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A 104: 3261-3266, 2007 (Pubitemid 46364147)
73. Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30: 1426-1447, 2008
74. Mérel P, Hoang-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, et al.: Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 13:211-216, 1995
75. Meyer TA, Canty PA, Wilkinson EP, Hansen MR, Rubinstein JT, Gantz BJ: Small acoustic neuromas: surgical outcomes versus observation or radiation. Otol Neurotol 27:380-392, 2006 (Pubitemid 43772463)
76. Moffat DA, Irving RM: The molecular genetics of vestibular schwannoma. J Laryngol Otol 109:381-384, 1995
77. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007 (Pubitemid 46972777)
78. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, et al.: The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15:968-980, 2001 (Pubitemid 32323547)
79. Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herlich P: Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the action of Ras and Rac. Cancer Res 67:520-527, 2007 (Pubitemid 46192188)
80. Morrissey TK, Levi AD, Nuijens A, Sliwkowski M, Bunge RP: Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2. Proc Natl Acad Sci U S A 92:1431-1435, 1995
81. Neff BA, Welling DB, Akhmametyeva E, Chang LS: The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level. Otol Neurotol 27: 197-208, 2006
82. Okada T, Lopez-Lago M, Giancotti FG: Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 171:361-371, 2005 (Pubitemid 41540027)
83. Okada T, You L, Giancotti FG: Shedding light on Merlin's wizardry. Trends Cell Biol 17:222-229, 2007 (Pubitemid 46679247)
84. Pearson MA, Reczek D, Bretscher A, Karplus PA: Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 101:259-270, 2000
85. Pelton PD, Sherman LS, Rizvi TA, Marchionni MA, Wood P, Friedman RA, et al.: Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene 17:2195-2209, 1998 (Pubitemid 28515373)
86. Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG II: Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 31:1135-1143, 2010
87. Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, Halpin C, Padera TP, Tyrrell A, et al.: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358-367, 2009
88. Propp JM, McCarthy BJ, Davis FG, Preston-Martin S: Descriptive epidemiology of vestibular schwannomas. Neuro Oncol 8:1-11, 2006 (Pubitemid 43158221)
89. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR: E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 23:1739-1748, 2004 (Pubitemid 38649637)
90. Qiu RG, Chen J, McCormick F, Symons M: A role for Rho in Ras transformation. Proc Natl Acad Sci U S A 92:11781- 11785, 1995
91. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, et al.: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515-521, 1993 (Pubitemid 23186636)
92. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al.: Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6:180-184, 1994 (Pubitemid 24188600)
93. Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, Zwarthoff E, et al.: Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J Cell Sci 110:2249-2260, 1997 (Pubitemid 27448369)
94. Schuknecht HF: Pathology of the Ear, ed 2. Philadelphia: Lea & Febiger, 1993
95. Scoles DR, Baser ME, Pulst SM: A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes. Neurology 47:544-546, 1996 (Pubitemid 26324058)
96. Seizinger BR, Martuza RL, Gusella JF: Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 322:644-647, 1986 (Pubitemid 16011448)
97. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, et al.: The Nf2 tumor suppressor, merlin, functions in Racdependent signaling. Dev Cell 1:63-72, 2001
98. Shimizu T, Seto A, Maita N, Hamada K, Tsukita S, Tsukita S, et al.: Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Biol Chem 277:10332-10336, 2002 (Pubitemid 34968150)
99. Slattery WH III, Fisher LM, Iqbal Z, Oppenhiemer M: Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 25:811-817, 2004 (Pubitemid 39223261)
100. Solares CA, Panizza B: Vestibular schwannoma: an understanding of growth should influence management decisions. Otol Neurotol 29:829-834, 2008
101. Speck O, Hughes SC, Noren NK, Kulikauskas RM, Fehon RG: Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity. Nature 421:83-87, 2003 (Pubitemid 36077089)
102. Stangerup SE, Tos M, Caye-Thomasen P, Tos T, Klökker M, Thomsen J: Increasing annual incidence of vestibular schwannoma and age at diagnosis. J Laryngol Otol 118:622-627, 2004 (Pubitemid 39280057)
103. Stangerup SE, Tos M, Thomsen J, Caye-Thomasen P: True incidence of vestibular schwannoma? Neurosurgery 67:1335-1340, 2010
104. Strasnick B, Glasscock ME III, Haynes D, McMenomey SO, Minor LB: The natural history of untreated acoustic neuromas. Laryngoscope 104:1115-1119, 1994 (Pubitemid 24284718)
105. Sughrue ME, Yeung AH, Rutkowski MJ, Cheung SW, Parsa AT: Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. A review. J Neurosurg 114:359-366, 2009
106. Takahashi K, Sasaki T, Mammoto A, Takaishi K, Kameyama T, Tsukita S, et al.: Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J Biol Chem 272:23371-23375, 1997 (Pubitemid 27392478)
107. Takahashi K, Suzuki K: Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. Exp Cell Res 226:214-222, 1996 (Pubitemid 26238945)
108. Tos M, Charabi S, Thomsen J: Incidence of vestibular schwannomas. Laryngoscope 109:736-740, 1999 (Pubitemid 29227919)
109. Tos M, Stangerup SE, Cayé-Thomasen P, Tos T, Thomsen J: What is the real incidence of vestibular schwannoma? Arch Otolaryngol Head Neck Surg 130:216-220, 2004 (Pubitemid 38182550)
110. Tos M, Thomsen J: Epidemiology of acoustic neuromas. J Laryngol Otol 98:685-692, 1984 (Pubitemid 14088498)
111. Tos M, Thomsen J, Charabi S: Incidence of acoustic neuromas. Ear Nose Throat J 71:391-393, 1992
112. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, et al.: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72: 791-800, 1993 (Pubitemid 23093886)
113. Turner CE: Paxillin interactions. J Cell Sci 113 (Pt 23):4139-4140, 2000
114. Twist EC, Ruttledge MH, Rousseau M, Sanson M, Papi L, Merel P, et al.: The neurofibromatosis type 2 gene is inactivated in schwannomas. Hum Mol Genet 3:147-151, 1994 (Pubitemid 24038157)
115. Uesaka T, Shono T, Suzuki SO, Nakamizo A, Niiro H, Mizoguchi M, et al.: Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol 83:259-266, 2007 (Pubitemid 46952236)
116. Vadlamudi R, Adam L, Talukder A, Mendelsohn J, Kumar R: Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase. Oncogene 18:7253-7264, 1999 (Pubitemid 30032104)
117. Vartanian T, Goodearl A, Viehöver A, Fischbach G: Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3. J Cell Biol 137:211-220, 1997 (Pubitemid 27167308)
118. von Recklinghausen F: Ueber die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. Berlin: A. Hirschundel, 1882
119. Welling DB: Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas). Laryngoscope 108:178-189, 1998
120. Welling DB, Guida M, Goll F, Pearl DK, Glasscock ME, Pappas DG, et al.: Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Hum Genet 98: 189-193, 1996 (Pubitemid 26237502)
121. Wilkinson JS, Reid H, Armstrong GR: Malignant transformation of a recurrent vestibular schwannoma. J Clin Pathol 57: 109-110, 2004 (Pubitemid 38091329)
122. Wishart J: Case of tumours in the skull, dura mater, and brain. Edinburg Med Surg J 18:393-397, 1822
123. Wong ET, Brem S: Taming glioblastoma: targeting angiogenesis. J Clin Oncol 25:4705-4706, 2007 (Pubitemid 350086470)
124. World Health Organization/National Neurofibromatosis Foundation: Prevention and control of neurofibromatosis: memorandum from a joint WHO/NNFF meeting. Bull World Health Organ 70:173-182, 1992
125. Yamakami I, Kobayashi E, Iwadate Y, Saeki N, Yamaura A: Hypervascular vestibular schwannomas. Surg Neurol 57:105-112, 2002 (Pubitemid 34211335)
126. Yeung AH, Sughrue ME, Kane AJ, Tihan T, Cheung SW, Parsa AT: Radiobiology of vestibular schwannomas: mechanisms of radioresistance and potential targets for therapeutic sensitization. Neurosurg Focus 27(6):E2, 2009